Aprea Therapeutics, Inc. Common stock
Symbol: APRE (NASDAQ)
1.56
▲ (3.31%) 0.050
Company Description:
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Key Stats
- Today's Open: $1.48
- Today's High: $1.62
- Today's Low: $1.545
- Today's Volume: 63.98K
- Yesterday Close: $1.51
- Yesterday High: $1.64
- Yesterday Low: $1.43
- Yesterday Volume: 288.72K
- Last Min Volume: 1
- Last Min High: $1.56
- Last Min Low: $1.56
- Last Min VWAP: $1.56
Company Profile
- Name: Aprea Therapeutics, Inc. Common stock
- Website: https://www.aprea.com
- Listed Date: 2019-10-03
- Location: DOYLESTOWN, PA
- Market Status: Active
- CIK Number: 0001781983
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $8.80M
- Round Lot: 100
- Outstanding Shares: 5.83M
- Asset Type: CS
RECENT FILINGS FOR APRE
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-15 | 8-K | View |
| 2025-09-08 | 8-K | View |
| 2025-08-13 | SCHEDULE 13G/A | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 8-K | View |
| 2025-06-09 | 4 | View |
| 2025-05-14 | SCHEDULE 13G/A | View |
| 2025-05-14 | 10-Q | View |
| 2025-05-14 | 8-K | View |
| 2025-04-22 | ARS | View |
| 2025-04-22 | DEFA14A | View |
| 2025-04-22 | DEF 14A | View |
Latest News on APRE